Immunovant, Inc.
IMVT
$15.08
$0.191.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.02M | 20.17M | 19.78M | 18.47M | 18.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 127.22M | 113.83M | 114.30M | 115.74M | 94.28M |
| Operating Income | -127.22M | -113.83M | -114.30M | -115.74M | -94.28M |
| Income Before Tax | -119.70M | -105.87M | -110.97M | -109.04M | -87.07M |
| Income Tax Expenses | 913.00K | 583.00K | 152.00K | 78.00K | 77.00K |
| Earnings from Continuing Operations | -120.61M | -106.45M | -111.12M | -109.12M | -87.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.61M | -106.45M | -111.12M | -109.12M | -87.15M |
| EBIT | -127.22M | -113.83M | -114.30M | -115.74M | -94.28M |
| EBITDA | -127.12M | -113.72M | -114.20M | -115.65M | -94.20M |
| EPS Basic | -0.71 | -0.64 | -0.76 | -0.75 | -0.60 |
| Normalized Basic EPS | -0.44 | -0.40 | -0.47 | -0.47 | -0.37 |
| EPS Diluted | -0.71 | -0.64 | -0.76 | -0.75 | -0.60 |
| Normalized Diluted EPS | -0.44 | -0.40 | -0.47 | -0.47 | -0.37 |
| Average Basic Shares Outstanding | 170.87M | 166.73M | 146.92M | 146.47M | 146.09M |
| Average Diluted Shares Outstanding | 170.87M | 166.73M | 146.92M | 146.47M | 146.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |